文献速递胸部肿瘤

两项奥希替尼II期注册研究中的EGFR突变分析用于前瞻性患者筛选

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
PubMed 文献 · J Thorac Oncol · 2017-05-17

在AURA extension和AURA2两项II期研究中,对既往治疗后进展的EGFR突变阳性晚期NSCLC患者进行中心T790M检测以筛选患者,AURA extension和AURA2的T790M检出率分别为64%和63%,汇总为63%,与既往EGFR TKI治疗或种族无关,cobas检测与二代测序参考方法相比具有高灵敏度和特异度。

要点

  • AURA extension和AURA2的T790M检出率分别为64%和63%,汇总为63%。
  • T790M检出率与种族无关(亚洲和非亚洲患者均为63%)。
  • 外显子19缺失背景下T790M检出率高于L858R突变(73% vs 58%)。

核心结论

  • 在两项研究中,晚期NSCLC患者的T790M突变检出率约为63%,且不受近期EGFR TKI治疗或种族影响。

研究设计与样本

  • 两项II期研究(AURA extension和AURA2)评估奥希替尼治疗EGFR T790M阳性晚期NSCLC,患者经中心T790M检测筛选。
  • AURA extension和AURA2分别有324例和373例患者的样本产生有效的cobas检测结果。
  • cobas检测结果与MiSeq二代测序参考方法进行比较。

主要发现

  • AURA extension和AURA2的T790M检出率分别为64%和63%,汇总为63%。
  • 亚洲和非亚洲患者的T790M检出率均为63%。
  • 既往EGFR TKI为阿法替尼、厄洛替尼和吉非替尼时,T790M检出率分别为69%、69%和63%。
  • 外显子19缺失背景下T790M检出率为73%,L858R突变背景下为58%(p = 0.0002)。
  • cobas检测与二代测序参考方法相比,T790M检测的阳性百分 agreement 分别为91%和89%,阴性百分 agreement 分别为97%和98%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib is an oral, central nervous system-active, EGFR tyrosine kinase inhibitor (TKI) for the treatment of EGFR T790M-positive advanced NSCLC. Here we have evaluated EGFR mutation frequencies in two phase II studies of osimertinib (AURA extension and AURA2). METHODS: After progression while receiving their latest line of therapy, patients with EGFR mutation-positive advanced NSCLC provided tumor samples for mandatory central T790M testing for the study selection criteria. Tumor tissue mutation analysis for patient selection was performed with the Roche cobas EGFR Mutation Test (European Conformity-in vitro diagnostic, labeled investigational use only) (Roche Molecular Systems, Pleasanton, CA). Patients should not have been prescreened for T790M mutation status. The cobas test results were compared with those of the MiSeq next-generation sequencing system (Illumina, San Diego, CA), which was used as a reference method. RESULTS: Samples from 324 and 373 patients screened for AURA extension and AURA2, respectively, produced valid cobas test results. The T790M detection rates were similar between AURA extension and AURA2 (64% and 63%, respectively). The pooled T790M rate was 63%, with no difference by ethnicity (63% for Asian and non-Asian patients alike) or immediately prior treatment with an EGFR TKI (afatinib, 69%; erlotinib, 69%; and gefitinib, 63%). A higher proportion of patients had T790M detected against a background of exon 19 deletions versus L858R mutation (73% versus 58% [p = 0.0002]). In both trials the cobas test demonstrated high sensitivity (positive percent agreement) and specificity (negative percent agreement) for T790M detection when compared with the next-generation sequencing reference method: positive percent agreement of 91% versus 89% and negative percent agreement of 97% versus 98%. CONCLUSIONS: In both trials, the rate of detection of T790M mutation in patients with advanced NSCLC was approximately 63% and was unaffected by immediately prior treatment with an EGFR TKI or ethnicity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Jenkins S, Yang JC, Jänne PA, et al. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. J Thorac Oncol. 2017. PMID: 28527899. doi:10.1016/j.jtho.2017.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。